3Garcia - Suarez J,Prieto A,Reyes E,et al.The xliniral outcome of autoinmmune thrombocytopenic purpura patients is related to their T all immunodeficiency. Br J Haematol, 1993,84: 464.
4Kuwana M, Okazaki Y, Kaburaki J,et al. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol, 2002 ; 168 (7) :3675-3682.
5Alves CR, Benevolo-De-Andrade TC, Alves JL, et al. Thl and Th2 immunological profile induced by cystelne proteinase in murine leishmaniasis. Parasite Immunol,2004;26(3) :127-135.
6Mosmann TR,Sad S. The expanding universe of T-cell subsets: Thl ,Th2 and more. lmmunol Today,1996;17(3):138-146.
7Nagata K, Hirai H. The second PGDz receptor CRTH2;structure, properties, and functions in leukocytes prostaglandins. Leukot Essent Fatty Acids, 2003 ; 69 (2-3) : 169- 177.
8Nagata K, Tanaka K, Ogawa K, et al. Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol, 1999 ; 162(3) : 1278-1286.
9Andersson PO, Stockelberg D, Jacobsson S, et al. A transforming growth factor-betaI-medlated bystander immune suppression could beassociated with remission of chronic idiopathic thrombocytopenic purpura. Ann Hematol, 2000; 79 (9) :507-513.
